Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal Neuropathy
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A phenome-wide association study (PheWAS) identified an association between a loss of
function variant in the human alpha 2B adrenergic receptor gene and trigeminal nerve
disorders. Guanfacine is the oldest alpha-2 adrenergic agonist in clinical use and is
approved for hypertension and attention deficit hyperactivity disorder. We hypothesize that
guanfacine will be an effective adjunct to lidocaine for the treatment of neuropathic pain by
enhancing and prolonging pain relief due to its activation of alpha-2 adrenergic receptors.
The objectives of the study will be to evaluate the efficacy and safety of guanfacine in
combination with lidocaine for trigeminal nerve block procedures for pain management in
trigeminal neuralgia patients. This study will evaluate the efficacy of guanfacine in
reducing acute pain and extending duration of pain relief when delivered in combination with
lidocaine as a trigeminal nerve block, measured by Visual Analog Scale (VAS) data collected
at specific time points after each injection.